Nektar Therapeutics (Nektar Therapeutics) Net Margin %

: -176.17% (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Nektar Therapeutics's Net Income for the three months ended in Dec. 2023 was $-42.08 Mil. Nektar Therapeutics's Revenue for the three months ended in Dec. 2023 was $23.89 Mil. Therefore, Nektar Therapeutics's net margin for the quarter that ended in Dec. 2023 was -176.17%.

The historical rank and industry rank for Nektar Therapeutics's Net Margin % or its related term are showing as below:

NKTR' s Net Margin % Range Over the Past 10 Years
Min: -514.03 Med: -191.73 Max: 57.09
Current: -306.31

NKTR's Net Margin % is ranked worse than
58.42% of 1027 companies
in the Biotechnology industry
Industry Median: -163.32 vs NKTR: -306.31

Nektar Therapeutics Net Margin % Historical Data

The historical data trend for Nektar Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => -384.47 [6] => -290.65 [7] => -514.03 [8] => -399.98 [9] => -306.31 )

Nektar Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

-384.47

-290.65

-514.03

-399.98

-306.31

Nektar Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-271.03	-634.52	-249.39	-189.85	-176.17

Competitive Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Net Margin % falls into.

Nektar Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nektar Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-276.056	/	90.122
	=	-306.31 %

Nektar Therapeutics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-42.079	/	23.885
	=	-176.17 %

Nektar Therapeutics (NAS:NKTR) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Nektar Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics (Nektar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

ITH:Germany

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Executives

Howard W Robin	director, officer: President & CEO
Jonathan Zalevsky	officer: Chief R&D Officer	455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson	officer: SVP & General Counsel	1613 RAY DRIVE, BURLINGAME CA 94010
Myriam Curet	director	1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner	officer: Chief Financial Officer	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen	officer: VP & Chief Accounting Officer	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Robert Chess	director, officer: Executive Chairman
Karin Eastham	director	C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie	officer: SVP, COO & CFO	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott	officer: SVP & Chief Commercial Officer	455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard	director	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer	director	6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau	director	15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein	officer: Chief Scientific Officer	129 ELSIE STREET, SAN FRANCISCO CA 94110